Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker OMER · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN NCT06209736 · C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glome… OMS906 study drug | OMER Omeros Corporation | Phase 2 | Terminated was recruiting | 3 | Apr 14, 2026 | Registry ↗ |
| Jul 16, 2026 | Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria NCT06298955 · Paroxysmal Nocturnal Hemoglobinuria OMS906 study drug | OMER Omeros Corporation | Phase 2 | Active, not recruiting | 25 | Dec 2026 | Registry ↗ |
| May 11, 2026 | Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria NCT05889299 · Paroxysmal Nocturnal Hemoglobinuria OMS906 | OMER Omeros Corporation | Phase 1 | Completed | 15 | Nov 3, 2025 | Registry ↗ |
| Mar 30, 2026 | Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS7… NCT02682407 · IgAN, LN OMS721 (narsoplimab) | OMER Omeros Corporation | Phase 2 | Terminated | 31 | Aug 25, 2020 | Registry ↗ |
| Mar 5, 2026 | Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab NCT04247906 · Hematopoietic Stem Cell Transplant Associated Thrombotic Mi… Narsoplimab | OMER Omeros Corporation | — | Approved for marketing | — | — | Registry ↗ |
| Dec 10, 2025 | Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome NCT03205995 · Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syn… OMS721 (narsoplimab) | OMER Omeros Corporation | Phase 3 | Terminated | 6 | Feb 2, 2021 | Registry ↗ |
| Dec 9, 2025 | Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy NCT03608033 · IgA Nephropathy OMS721, Vehicle (D5W or saline) | OMER Omeros Corporation | Phase 3 | Terminated | 360 | Jan 12, 2024 | Registry ↗ |
| Oct 1, 2025 | Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Re… NCT05972967 · Paroxysmal Nocturnal Hemoglobinuria OMS906 | OMER Omeros Corporation | Phase 2 | Completed | 12 | Oct 10, 2024 | Registry ↗ |
| Mar 25, 2025 | Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Ce… NCT05855083 · Thrombotic Microangiopathies, Hematopoietic Stem Cell Trans… Biological: narsoplimab | OMER Omeros Corporation | Phase 2 | Recruiting | 18 | Dec 2025 | Registry ↗ |
| Aug 28, 2024 | Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies NCT02222545 · Thrombotic Microangiopathies OMS721 | OMER Omeros Corporation | Phase 2 | Completed | 58 | Jan 30, 2020 | Registry ↗ |
| Jul 22, 2021 | A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extrac… NCT02132312 · Unilateral Cataract Extraction, Congenital Cataract OMS302, Phenylephrine HCl | OMER Omeros Corporation | Phase 3 | Completed | 78 | Sep 12, 2016 | Registry ↗ |
| Oct 26, 2018 | Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing… NCT01406561 · Meniscal Tear OMS103HP-S, Vehicle | OMER Omeros Corporation | Phase 3 | Completed | 344 | Nov 2012 | Registry ↗ |
| Oct 22, 2018 | Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease NCT02074410 · Huntington's Disease OMS643762, Placebo | OMER Omeros Corporation | Phase 2 | Terminated | 22 | Oct 15, 2014 | Registry ↗ |
| Oct 22, 2018 | Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Sub… NCT01952132 · Schizophrenia OMS643762, Placebo | OMER Omeros Corporation | Phase 2 | Completed | 40 | Apr 2014 | Registry ↗ |
| Mar 13, 2018 | Intraoperative Floppy Iris Syndrome Undergoing Intraocular Lens Replacement Surgery NCT02093689 · Intraocular Lens Replacement, Intraoperative Floppy Iris Sy… Part 1 OMS302, Part 2 OMS302 | OMER Omeros Corporation | Phase 3 | Terminated | 18 | Aug 2014 | Registry ↗ |
| Jun 14, 2017 | Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement… NCT01579565 · Intraocular Lens Replacement OMS302, Placebo | OMER Omeros Corporation | Phase 3 | Completed | 416 | Nov 2012 | Registry ↗ |
16 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:46 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances